Cancer Res Treat.  2025 Jan;57(1):291-292. 10.4143/crt.2024.1048.

Reply to Commentary on “Metronomic S-1 Adjuvant Chemotherapy Improves Survival in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma”

• Wu SG

• KMID: 2564602
• DOI: http://doi.org/10.4143/crt.2024.1048

Reference

References

1. Yu YF, Wu P, Zhuo R, Wu SG. Metronomic S-1 adjuvant chemotherapy improves survival in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer Res Treat. 2024; 56:1058–67.

2. Topkan E, Somay E, Durankus NK, Selek U. Commentary on “metronomic S-1 adjuvant chemotherapy improves survival in patients with locoregionally advanced nasopharyngeal carcinoma.”. Cancer Res Treat. 2025; 57:289–90.

3. Li WZ, Lv X, Hu D, Lv SH, Liu GY, Liang H, et al. Effect of induction chemotherapy with paclitaxel, cisplatin, and capecitabine vs cisplatin and fluorouracil on failure-free survival for patients with stage IVA to IVB nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial. JAMA Oncol. 2022; 8:706–14.

4. Dai J, Zhang B, Su Y, Pan Y, Ye Z, Cai R, et al. Induction chemotherapy followed by radiotherapy vs chemoradiotherapy in nasopharyngeal carcinoma: a randomized clinical trial. JAMA Oncol. 2024; 10:456–63.

5. Wang L, Zhuang H, Xu X, Zhou J, Jiao Y. Efficacy and survival analysis of nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma. Front Oncol. 2023; 13:1129649.

6. Delgado A, Guddati AK. Clinical endpoints in oncology: a primer. Am J Cancer Res. 2021; 11:1121–31.

7. Jin YN, Qiang MY, Wang Y, Lin YJ, Jiang RW, Cao WW, et al. The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis. Cancer Immunol Immunother. 2024; 73:125.